January 7, 2022
Frame Therapeutics’ first clinical trial submission (short title ‘FRAME-001’) has officially been approved by the Dutch authorities at the CCMO (Central Committee on Research Involving Human Subjects). This trial registered as NCT04998474 will evaluate Frame Therapeutics’ personalized neoantigen based approach in ~15 patients with non-small-cell lung cancer. FRAME-001 will be carried out in collaboration with four leading academic centers in the Netherlands: Erasmus University Medical Center Rotterdam, University Medical Center Groningen, Leiden University Medical Center and the Netherlands Cancer Institute in Amsterdam. Activating enrollment is planned in early 2022. Moving from preclinical to clinical stage represents another critical milestone in the development of the company.
More information and details concerning FRAME-001 can be found in the clinicaltrials.gov registry via this link. We will keep you updated on this website, via our LinkedIn page and we are always happy to answer any trial-related questions via firstname.lastname@example.org.